$ZURA
Zura Bio Ltd

2023 Q3 Form 10-Q Financial Statement

#000141057823001829 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.220M $5.680M $1.072M
YoY Change 1044.22% 429.95% 5499.79%
% of Gross Profit
Research & Development $3.965M $28.23M $85.00K
YoY Change 855.42% 33111.76%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.19M $33.91M $1.072M
YoY Change 1773.99% 3063.37% 5499.79%
Operating Profit -$10.19M -$33.91M -$1.072M
YoY Change 1774.0% 3063.36% 5499.52%
Interest Expense $1.920M -$530.0K $3.342M
YoY Change 91.6% -115.86%
% of Operating Profit
Other Income/Expense, Net $1.917M -$120.0K $3.342M
YoY Change 91.3% -103.59%
Pretax Income -$8.270M -$34.03M $2.271M
YoY Change -1903.83% -1598.52% -11963.01%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.300M -$34.00M $2.271M
YoY Change -1910.37% -1597.41% -11962.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18 -$1.31 -$9.54
Diluted Earnings Per Share -$0.18 -$1.31 $131.6K
COMMON SHARES
Basic Shares Outstanding 43.09M 27.05M 97.00K
Diluted Shares Outstanding 46.88M 34.30M 97.00K

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.9M $112.8M $220.7K
YoY Change 139456.75% 51000.84% 783.67%
Cash & Equivalents $103.9M $112.8M $220.7K
Short-Term Investments
Other Short-Term Assets $700.0K $500.0K $215.9K
YoY Change 472.83% 131.63%
Inventory
Prepaid Expenses $215.9K
Receivables
Other Receivables
Total Short-Term Assets $104.6M $113.3M $436.6K
YoY Change 53085.53% 25857.98% 1648.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $139.6M
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $0.00 $0.00 $139.6M
YoY Change -100.0% -100.0% 99768.06%
TOTAL ASSETS
Total Short-Term Assets $104.6M $113.3M $436.6K
Total Long-Term Assets $0.00 $0.00 $139.6M
Total Assets $104.6M $113.3M $140.0M
YoY Change -25.55% -19.07% 84893.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.645M $7.051M $30.00K
YoY Change 933.03% 23403.33% -58.11%
Accrued Expenses $728.9K
YoY Change 24626.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $179.0K
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.01M $19.94M $1.041M
YoY Change 1165.51% 1815.75% 442.28%
LONG-TERM LIABILITIES
Long-Term Debt $2.000M $2.100M $0.00
YoY Change
Other Long-Term Liabilities $6.375M
YoY Change
Total Long-Term Liabilities $2.000M $2.100M $6.375M
YoY Change -66.99% -67.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.01M $19.94M $1.041M
Total Long-Term Liabilities $2.000M $2.100M $6.375M
Total Liabilities $18.96M $22.01M $7.416M
YoY Change 156.11% 196.79% 3763.64%
SHAREHOLDERS EQUITY
Retained Earnings -$95.00M -$86.80M -$6.879M
YoY Change 1236.6% 1161.72% 13084.16%
Common Stock $4.000K $4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.21M $68.91M -$6.879M
YoY Change
Total Liabilities & Shareholders Equity $104.6M $113.3M $140.0M
YoY Change -25.55% -19.07% 84893.76%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$8.300M -$34.00M $2.271M
YoY Change -1910.37% -1597.41% -11962.39%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.570M -$5.170M -$472.9K
YoY Change 861.61% 993.32%
INVESTING ACTIVITIES
Capital Expenditures $2.250M $5.750M
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.250M -$5.750M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.130M 79.77M 179.0K
YoY Change -3514.07% 44461.76%
NET CHANGE
Cash From Operating Activities -2.570M -5.170M -472.9K
Cash From Investing Activities -2.250M -5.750M
Cash From Financing Activities -4.130M 79.77M 179.0K
Net Change In Cash -8.950M 68.85M -293.9K
YoY Change 6017.98% -23529.52%
FREE CASH FLOW
Cash From Operating Activities -$2.570M -$5.170M -$472.9K
Capital Expenditures $2.250M $5.750M
Free Cash Flow -$4.820M -$10.92M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001855644
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
zura Transfers Between Level2 And Level3
TransfersBetweenLevel2AndLevel3
0
CY2022 zura Transfers Between Level2 And Level3
TransfersBetweenLevel2AndLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
13510415
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
13510415
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43093685
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
383479
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40598
dei Entity Registrant Name
EntityRegistrantName
ZURA BIO LIMITED
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1725736
dei Entity Address Address Line1
EntityAddressAddressLine1
1489 W. Warm Springs Rd. #110
dei Entity Address City Or Town
EntityAddressCityOrTown
Henderson
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89014
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
757-6133
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43093685
CY2023Q2 us-gaap Cash
Cash
112802000
CY2022Q4 us-gaap Cash
Cash
1567000
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
530000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
209000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
113332000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1776000
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
3486000
CY2023Q2 us-gaap Assets
Assets
113332000
CY2022Q4 us-gaap Assets
Assets
5262000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
19940000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4428000
CY2022Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
7756000
CY2022Q4 zura Research And Development License Consideration Liability
ResearchAndDevelopmentLicenseConsiderationLiability
2634000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19940000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14818000
CY2023Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
2069000
CY2023Q2 us-gaap Liabilities
Liabilities
22009000
CY2022Q4 us-gaap Liabilities
Liabilities
14818000
CY2023Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
13510415
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12500000
CY2023Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
20875000
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43093685
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1884649
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
383479
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
155654000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86751000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32056000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
68907000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-32056000
CY2023Q2 us-gaap Minority Interest
MinorityInterest
1541000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70448000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32056000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113332000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5262000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28230000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33114000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7585000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5675000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
842000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8510000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1161000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
33905000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
927000
us-gaap Operating Expenses
OperatingExpenses
41624000
us-gaap Operating Expenses
OperatingExpenses
8746000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33905000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-927000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41624000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8746000
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
412000
CY2022Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
403000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
532000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
355000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-120000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2196000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34025000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-925000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43820000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8744000
CY2023Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-34025000
CY2022Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-925000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-43820000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-8744000
us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-203000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34025000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-925000
us-gaap Net Income Loss
NetIncomeLoss
-43617000
us-gaap Net Income Loss
NetIncomeLoss
-8744000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
CY2023Q2 zura Deemed Dividend To Redeemable Noncontrolling Interest
DeemedDividendToRedeemableNoncontrollingInterest
10875000
zura Deemed Dividend To Redeemable Noncontrolling Interest
DeemedDividendToRedeemableNoncontrollingInterest
10875000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-44900000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-925000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54695000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8744000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.54
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-162.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-162.30
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34303125
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34303125
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97004
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97004
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19012464
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19012464
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53874
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53874
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32056000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
14686000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4000000.0
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
48351000
zura Stock Issued During Period Value Research And Development License Consideration Liability
StockIssuedDuringPeriodValueResearchAndDevelopmentLicenseConsiderationLiability
4488000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2001000
zura Stock Issued Transaction Costs
StockIssuedTransactionCosts
9800000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8088000
us-gaap Net Income Loss
NetIncomeLoss
-43617000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
zura Value Of Issued Call Right
ValueOfIssuedCallRight
1541000
zura Adjustment Of Deemed Dividend To Redeemable Noncontrolling Interest
AdjustmentOfDeemedDividendToRedeemableNoncontrollingInterest
-10875000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70448000
CY2022Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
309000
us-gaap Net Income Loss
NetIncomeLoss
-8744000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-8435000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
27855000
CY2023Q2 zura Stock Issued Transaction Costs
StockIssuedTransactionCosts
9800000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7908000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34025000
CY2023Q2 zura Value Of Issued Call Right
ValueOfIssuedCallRight
1541000
CY2023Q2 zura Adjustment Of Deemed Dividend To Redeemable Noncontrolling Interest
AdjustmentOfDeemedDividendToRedeemableNoncontrollingInterest
-10875000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70448000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7819000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
309000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-925000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-8435000
CY2023Q2 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
us-gaap Profit Loss
ProfitLoss
-43820000
us-gaap Profit Loss
ProfitLoss
-8744000
zura Research And Development Expense On Acquired License
ResearchAndDevelopmentExpenseOnAcquiredLicense
27381000
zura Research And Development Expense On Acquired License
ResearchAndDevelopmentExpenseOnAcquiredLicense
7500000
zura Anti Dilution Share Issuance Compensation
AntiDilutionShareIssuanceCompensation
2186000
us-gaap Share Based Compensation
ShareBasedCompensation
2498000
us-gaap Share Based Compensation
ShareBasedCompensation
309000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
zura Fair Value Adjustment Of Share Based Payment Liability
FairValueAdjustmentOfShareBasedPaymentLiability
1854000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
355000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
401000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
321000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-406000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
371000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8430000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-588000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5750000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5750000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
10000000
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
63846000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56683000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
16070000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000000
zura Payment Of Deferred Transaction Costs
PaymentOfDeferredTransactionCosts
1184000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
125415000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
111235000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4412000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1567000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112802000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4412000
us-gaap Stock Issued1
StockIssued1
2500000
zura Conversion Of Series One Convertible Preferred Shares For Ordinary Shares
ConversionOfSeriesOneConvertiblePreferredSharesForOrdinaryShares
14686000
zura Accrued License Consideration
AccruedLicenseConsideration
12250000
zura Non Cash Transfers To Redeemable Noncontrolling Interest
NonCashTransfersToRedeemableNoncontrollingInterest
10875000
zura Issuance Of Shares For Consideration License
IssuanceOfSharesForConsiderationLicense
7840000
zura Share Based Equity Issuance Costs
ShareBasedEquityIssuanceCosts
5590000
zura Settlement Of Research And Development License Consideration Liability
SettlementOfResearchAndDevelopmentLicenseConsiderationLiability
4488000
zura Transaction Costs Include In Accounts Payable
TransactionCostsIncludeInAccountsPayable
4122000
zura Transaction Costs Include In Accounts Payable
TransactionCostsIncludeInAccountsPayable
1144000
zura Reclassification Of Deferred Transaction Costs To Additional Paid In Capital
ReclassificationOfDeferredTransactionCostsToAdditionalPaidInCapital
4015000
zura Assumption Of Public And Private Placement Warrants In Connection With Business Combination
AssumptionOfPublicAndPrivatePlacementWarrantsInConnectionWithBusinessCombination
3715000
zura Reclassification Of Public Warrant Liability To Equity
ReclassificationOfPublicWarrantLiabilityToEquity
2001000
zura Issuance Of Call Right To Noncontrolling Interest
IssuanceOfCallRightToNoncontrollingInterest
1541000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86800000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32100000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34000000.0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-900000
us-gaap Net Income Loss
NetIncomeLoss
-43600000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-8700000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112800000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56700000
CY2023Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
79900000
zura Significant Of Accounting Policies
SignificantOfAccountingPolicies
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Significant Accounting Policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Except for the addition of the Business Combination, the addition of public warrants, private placement warrants, and pre-funded warrants (collectively, the “Warrants”), and the addition of stock options with market-based performance conditions, there have been no significant changes in the Company’s significant accounting policies from those that were disclosed in Note 2, Summary of Significant Accounting Policies, included in the Company’s audited consolidated financial statements that were included in the Company’s Current Report on Form 8-K filed with the SEC on April 6, 2023.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13893786
CY2022Q1 zura Temporary Equity Number Of Votes Per Share
TemporaryEquityNumberOfVotesPerShare
1
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21889478
CY2023Q2 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023Q1 zura Number Of Ordinary Shares Issued And Outstanding Immediately Following Business Combination
NumberOfOrdinarySharesIssuedAndOutstandingImmediatelyFollowingBusinessCombination
27052155
CY2023Q1 zura Percentage On Outstanding Shares
PercentageOnOutstandingShares
1.000
zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
CY2022 zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000000.0
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
7756000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-10000000
zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2200000
zura Gain Or Loss On Remeasurement Of Research And Development License Consideration Liability
GainOrLossOnRemeasurementOfResearchAndDevelopmentLicenseConsiderationLiability
1900000
CY2023Q1 zura Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Assumptions
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAssumptions
1714000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-177000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1537000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
532000
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2069000
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2022Q1 us-gaap Temporary Equity Liquidation Preference Per Share
TemporaryEquityLiquidationPreferencePerShare
131
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7051000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2010000
CY2022Q4 zura Accrued Offering Costs Current
AccruedOfferingCostsCurrent
655000
CY2022Q4 zura Accrued Payroll Cost Current
AccruedPayrollCostCurrent
260000
CY2023Q2 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
10000000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1210000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
308000
CY2023Q2 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
713000
CY2022Q4 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
490000
CY2023Q2 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
567000
CY2022Q4 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
141000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
206000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
113000
CY2023Q2 zura Accrued Consulting Costs Current
AccruedConsultingCostsCurrent
193000
CY2022Q4 zura Accrued Consulting Costs Current
AccruedConsultingCostsCurrent
451000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
19940000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4428000
CY2023Q2 us-gaap Minority Interest
MinorityInterest
1500000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
0
CY2023Q1 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
267939
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 zura Temporary Equity Minimum Gross Aggregate Subscription Of Ordinary Shares Required For Conversion Of Temporary Equity
TemporaryEquityMinimumGrossAggregateSubscriptionOfOrdinarySharesRequiredForConversionOfTemporaryEquity
50000000.0
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2319000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
309000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4685000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
309000
zura Selling Price Per Share
SellingPricePerShare
2.040724
CY2023Q2 us-gaap Redeemable Noncontrolling Interest Equity Redemption Value
RedeemableNoncontrollingInterestEquityRedemptionValue
20900000
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Redemption Value
RedeemableNoncontrollingInterestEquityRedemptionValue
10000000.0

Files In Submission

Name View Source Status
zura-20230630_lab.xml Edgar Link unprocessable
zura-20230630_cal.xml Edgar Link unprocessable
0001410578-23-001829-index-headers.html Edgar Link pending
0001410578-23-001829-index.html Edgar Link pending
0001410578-23-001829.txt Edgar Link pending
0001410578-23-001829-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zura-20230630.xsd Edgar Link pending
zura-20230630x10q.htm Edgar Link pending
zura-20230630xex31d1.htm Edgar Link pending
zura-20230630xex31d2.htm Edgar Link pending
zura-20230630xex32d1.htm Edgar Link pending
zura-20230630xex32d2.htm Edgar Link pending
zura-20230630_def.xml Edgar Link unprocessable
zura-20230630_pre.xml Edgar Link unprocessable
zura-20230630x10q_htm.xml Edgar Link completed